Cybin (CYBN) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free CYBN Stock Alerts $0.35 0.00 (0.00%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort InterestStock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative April 5, 2024 | theglobeandmail.comLSD, Ecstasy, magic mushrooms coming to a clinic near you? Legalization nears for psychedelicsApril 1, 2024 | msn.comInside George Soros’ Portfolio: His Top 8 Stock PicksApril 1, 2024 | msn.com10 Best Stocks To Buy Under $1March 31, 2024 | msn.comFan invades the pitch smoking marijuana and sniffing glue in BrazilMarch 30, 2024 | msn.comPsychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And MoreMarch 20, 2024 | msn.comPsyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And MoreMarch 15, 2024 | msn.comCybin initiates Phase 2 study for psychedelic drug DMTMarch 13, 2024 | msn.comFDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data & Canadian $150M Private PlacementMarch 13, 2024 | msn.comCybin spikes after FDA breakthrough tag for psychedelic therapyMarch 13, 2024 | finance.yahoo.comAnnounces Oversubscribed Private Placement of U.S. $150 MillionMarch 1, 2024 | marketbeat.comFY2024 EPS Estimates for Cybin Inc. Lowered by Cantor Fitzgerald (NYSEAMERICAN:CYBN)Cybin Inc. (NYSEAMERICAN:CYBN - Free Report) - Investment analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for shares of Cybin in a note issued to investors on Tuesday, February 27th. Cantor Fitzgerald analyst C. Duncan now expects that the company will post eFebruary 27, 2024 | finance.yahoo.comCybin to Present at the TD Cowen 44th Annual Health Care ConferenceFebruary 22, 2024 | benzinga.comCybin Stock (AMEX:CYBN) Earnings Dates and Earning CallsFebruary 17, 2024 | finance.yahoo.comALPN Mar 2024 25.000 callFebruary 16, 2024 | benzinga.comCybin Inc. Q3 Earnings: Clinical Advances Amid Financial LossJanuary 9, 2024 | msn.comCybin Inc's Two Deuterated Psychedelic Molecules Achieve Positive Topline Clinical ResultsJanuary 4, 2024 | finance.yahoo.comCybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development ProgramsDecember 5, 2023 | finance.yahoo.comCybin Announces Four Poster Presentations at the 2023 American College of Neuropsychopharmacology Annual Meeting Including CYB003 Phase 2 Topline ResultsNovember 16, 2023 | finance.yahoo.comCybin to Release Phase 2 Topline Safety and Efficacy Data for CYB003 in Major Depressive Disorder and Host R&D Briefing on November 30, 2023November 15, 2023 | finance.yahoo.comCybin Announces Poster Presentation at Neuroscience 2023 Annual MeetingNovember 14, 2023 | benzinga.comThinking about buying stock in Hanryu Holdings, Absci Corp, Spero Therapeutics, BioXcel Therapeutics, or Cybin?October 31, 2023 | finance.yahoo.comCybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single DoseOctober 31, 2023 | finance.yahoo.comCybin Announces Unprecedented Positive Interim Phase 2 Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Full Topline Data on Track for Q4 2023October 25, 2023 | finance.yahoo.comCybin Announces Grant of Two New United States Patents Protecting its Deuterated DMT ProgramOctober 23, 2023 | msn.comPsychedelic drug developer Cybin completes acquisition of Small PharmaOctober 23, 2023 | finance.yahoo.comCybin Completes Acquisition of Small Pharma Inc. to Create International Clinical-stage Leader in Novel Psychedelic TherapeuticsOctober 13, 2023 | benzinga.comCybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected DatesOctober 3, 2023 | benzinga.comSteve Cohen Keeps Betting On Biopharma With Purchase Of 119M+ Bionomics SharesSeptember 21, 2023 | finance.yahoo.comCybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive DisorderAugust 31, 2023 | msn.comPsilocybin in depression: Study shows lasting benefitAugust 28, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trade Resumption - CYBNAugust 28, 2023 | finance.yahoo.comCanadian Investment Regulatory Organization Trading Halt - CYBN Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address The Overlooked Retirement Asset You Probably Don’t Own (Ad)4 out of 5 Americans believe we’re on the brink of a retirement crisis. Luckily, in these unprecedented times, we have an unprecedented solution. Once considered a “fringe” investment, the crypto market is now taking the world by storm. Click here to access the Crypto Retirement Blueprint now. CYBN Media Mentions By Week CYBN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYBN News Sentiment▼0.000.42▲Average Medical News Sentiment CYBN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYBN Articles This Week▼01▲CYBN Articles Average Week Get Cybin News Delivered to You Automatically Sign up to receive the latest news and ratings for CYBN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RPTX News Today RAPT News Today CRVO News Today INCR News Today ELTP News Today RGLS News Today CYDY News Today IMAB News Today CTMX News Today MCRB News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:CYBN) was last updated on 5/19/2024 by MarketBeat.com Staff From Our Partners[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaUrgent Nvidia WarningAltimetryForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressMost important medical advance in 100 yearsThe Oxford Club41 banks launch ‘crypto dollar’Stansberry ResearchHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cybin Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
